Panu Hendolin - Biohit Oyj Executive
| BIOBV Stock | EUR 2.33 0.00 0.00% |
Executive
Mr. Panu Hendolin has served as Head of Research and Development and Member of the Management Team at Biohit Oyj since April 17, 2012. He previously was Head of Research and Development, Diagnostics at the Company from 2007 to 2008. He worked as a Postdoctoral Researcher at the A. I. Virtanen Institute for Molecular Sciences at the University of Eastern Finland, in several product development and managerial positions at Jurilab Oy Ltd and for the last three and a half years as the Technical Manager responsible for product development at Danaher Corporationrationrations Innotrac Diagnostics. He holds a Doctorate of Philosophy degree in Molecular Medicine. since 2012.
| Age | 52 |
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 358 9773 861 |
| Web | https://www.biohithealthcare.com |
Biohit Oyj Management Efficiency
The company has return on total asset (ROA) of 0.0652 % which means that it generated a profit of $0.0652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0645 %, meaning that it generated $0.0645 on every $100 dollars invested by stockholders. Biohit Oyj's management efficiency ratios could be used to measure how well Biohit Oyj manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | EXECUTIVE Age | ||
| Lasse Luukkainen | Kesko Oyj | 40 | |
| Juha Makela | UPM Kymmene Oyj | 61 | |
| John Lapvetelainen | Sampo Oyj A | 57 | |
Management Performance
| Return On Equity | 0.0645 | |||
| Return On Asset | 0.0652 |
Biohit Oyj B Leadership Team
Elected by the shareholders, the Biohit Oyj's board of directors comprises two types of representatives: Biohit Oyj inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biohit. The board's role is to monitor Biohit Oyj's management team and ensure that shareholders' interests are well served. Biohit Oyj's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biohit Oyj's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Graham Johnson, Managing Director of Biohit Healthcare Ltd. | ||
| Ilari Patrakka, Sales and Marketing Director, Member of the Management Team | ||
| Panu Hendolin, Head of Research and Development, Member of the Management Team | ||
| Jussi Hahtela, Chief Officer | ||
| Yulia Kubacheva, Head Russia | ||
| Jussi Sorvo, Chief Officer | ||
| Pr MD, Deputy Founder |
Biohit Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biohit Oyj a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0645 | |||
| Return On Asset | 0.0652 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.1 % | |||
| Current Valuation | 20.88 M | |||
| Shares Outstanding | 12.07 M | |||
| Shares Owned By Insiders | 47.13 % | |||
| Price To Earning | 11.00 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 2.16 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biohit Stock
Biohit Oyj financial ratios help investors to determine whether Biohit Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biohit with respect to the benefits of owning Biohit Oyj security.